News

Fallopian Tube Cancer Pipeline Outlook Report 2025: Key 70+ Companies And Breakthrough Therapies Shaping The Future Landscape

DelveInsight's,“ Fallopian Tube Cancer Pipeline Insight 2025 ” report provides comprehensive insights about 70+ Fallopian ...
Fierce Pharma1d

Pfizer and Astellas' Padcev, plus Keytruda, delivers 'breakthrough' win in new bladder cancer use

The rising bladder cancer star that is the combination of Pfizer and Astellas’ Padcev and Merck’s Keytruda is looking to set ...
CURE2h

Keytruda and Padcev Generate Positive Topline Findings in Bladder Cancer

Keytruda and Padcev generated promising topline results for those with muscle-invasive bladder cancer who are ineligible for ...

IO Biotech says cancer vaccine with Merck’s Keytruda outperformed in late-stage study

IO Biotech (IOBT) stock rallies as cancer vaccine, Cylembio, with Merck's (MRK) Keytruda outperforms in a late-stage trial ...

Merck, Pfizer-Backed Therapy Improves Outcomes For Cisplatin-Ineligible Bladder Cancer Patients

Merck's Phase 3 trial shows Keytruda plus Padcev improves survival in muscle-invasive bladder cancer patients ineligible for ...

Pfizer, Astellas post late-stage trial win for Padcev with Merck’s Keytruda in bladder cancer

Pfizer (PFE) stock is in focus as the company and Astellas (ALPMF) post a late-stage trial win for their cancer drug Padcev ...

Merck, Pfizer, Astellas Drug Combo Hits Key Goals in Bladder Cancer

Merck in 2019 inked a deal to evaluate the combination of its blockbuster cancer drug Keytruda with Pacdev from Astellas and Seagen, which Pfizer acquired in a $43 billion deal that closed in late ...

Pfizer’s Padcev Plus Keytruda Extends Bladder Cancer Survival

The combination of Padcev, a bladder cancer drug from Pfizer Inc. and Astellas Pharma Inc., and Merck & Co.’s blockbuster ...